



Mirror Mirror on the Wall: Who's the FDA's Fairest ADF of All?

Mark Garofoli, PharmD, MBA, BCGP, CPE

1

Faculty



- Family of 8 Pharmacists
- Wife, In-Laws, & Cousins
- Family Vineyard in the Marche Region of Italy



2

Disclosures

- Nothing to disclose

This presentation was not a part of the presenter's official duties at the WVU and does not represent the opinion of WVU



3

Opinions...

I have personal and professional opinions on pain management. However, some things are better left NSAID.



4

Learning Objectives

- Identify the seven current types of abuse-deterrent formulations.
- Recall all available abuse-deterrent formulation (ADF) opioid medications, with particular attention to the select few that are both FDA approved specifically as ADF opioid medications and available on the U.S. market.
- Discuss common methods of manipulation of abuse-deterrent formulation (ADF) opioid medications.



5

CDC MME Thresholds & Driving Speed Limits

Avoid
Increasing
Speed Limits ≥ 90 MEDD

Caution
50 MEDD



6

CDC MME Thresholds & Driving Speed Limits

Caution 50 MEDD

Avoid increasing 90 MEDD

SEAT BELTS SAVE LIVES
BUCKLE UP EVERY TIME

Painweek

7

Driving & Opioid Risk Reduction

PDMP Review
Physical Exam
Urine Drug Screening
Use Caution with Methadone
Short Duration of Initial Opioid
Avoid Sedative Co-Prescribing
Patient & Provider Agreement/Contract
MEDD Cautionary Threshold
Gradual Tapering Plan
Abuse-Deterrent Formulations

SEAT BELTS SAVE LIVES
BUCKLE UP EVERY TIME

Painweek

Adapted from <https://www.cdc.gov/mmwr/summaries/s0911a051a11.htm>

8

Opioid Abuse Transition

Research

Original Investigation

The Changing Face of Heroin Use in the United States
A Retrospective Analysis of the Past 50 Years

Theodore J. Cicero, PhD; Matthew S. Ellis, MPE; Hilary L. Surratt, PhD; Steven P. Kurtz, PhD

↓

75% of Heroin Users Started with Prescription Opioids

Painweek

© Cicero et al. 2019. The Changing Face of Heroin Use in the United States. JAMA December 10, 2019

9

Opioid Abuse Transition

Research

Original Investigation
The Changing Face of Heroin Use in the United States
 A Retrospective Analysis of the Past 50 Years

Theodore J. Cicero, PhD, Matthew S. Ellis, MPE, Hilary L. Surratt, PhD, Steven P. Kurtz, PhD

75% of Heroin Users
 Started with
 Prescription Opioids

Family, Friends, Theft ???

Healthcare Professional(s)

PainWeek © Cicero et al. (2014). The Changing Face of Heroin Use in the United States. JAMA Psychiatry. 71:129.

10

Where are these opioids coming from...

Friend/Relative (Free)

HEALTHCARE
 PROFESSIONAL
 ~1/3rd

PainWeek 2017 DEA National Drug Threat Assessment. https://www.dea.gov/oc/OIR-040-17_2017-NDTA.pdf

11


Opioid Abuse Transition

Hydrocodone Combo Tablets \$5-10/Tab	Oxycodone Combo IR Products \$10-15/Tab	Oxycodone Sole ER/IR Products \$1.50/mg	Heroin (\$10/Bag)
---	--	--	----------------------

ADFs

PainWeek Shah A, et al. Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use - United States, 2000-2015. Morbidity & Mortality Weekly Report. 2017;66(33):245-249. www.cdc.gov/mmwr

12



16

The Early “ADFs”

Hydrocodone & homatropine

- Tussigon tablets 5mg/1.5mg (FDA 1985)
- Hydromet liquid 5mg/1.5mg per 5ml (FDA 1943, generic 1983)
- Homatropine
 - Anticholinergic similar to Atropine (Aversion)

PainWeek | <https://www.fda.gov/drugs/druginf/infomaterials/drugclass.com/030506.htm>

17

The Early “ADFs”

Phenylpiperidine opioids (diarrhea treatment)

- Lomotil® (diphenoxylate & atropine, 1960)
- Motofen® (difenoxyin & atropine, 1978): metabolite of diphenoxylate
- Atropine
 - Produces *dysphoria* in large doses (aversion)
 - Anticholinergic: blurred vision, constipation, visual disturbances

PainWeek | <https://www.fda.gov/drugs/druginf/infomaterials/drugclass.com/030506.htm>

18

The Early “ADF’s”

Fentanyl with droperidol

- Dr. Robert Dripps (U of Penn) strong opponent due to abuse concerns
- Dr. Janssen (Janssen Pharmaceuticals) & Dr. Dripps developed the combination product of droperidol to fentanyl in a 50:1 ratio (FDA approved 1968)
- Dr. de Castro (Europe) recommended ratio based on his patient treatments including the droperidol to produce dysphoria if abused
- FDA later approved fentanyl as solo products



Shelley, T. The Fentanyl Story. The Journal of Pain, Vol 15, No 12 (December), 2014 pp 1219-1226.

19

The Early “ADFs”

Pentazocine and naloxone (FDA approved in 1982)


- Pentazocine single product
 - Kappa agonist, mu antagonist
 - Single product pentazocine FDA approved 1967
 - Observed to be crushed, mixed w/ antihistamine pyribenzamine, & injected
 - “Pinks & blues”
 - 1st DEA reclassification: pentazocine (single product) to CIV in 1979



https://www.fda.gov/oc/opa/foia/foia-information-for-oc-requests/200808.html

20

FDA Opioid Timeline



https://www.fda.gov/oc/opa/foia/foia-information-for-oc-requests/200808.html

21

The Opana Story

2017 (March)

- Endo presented post-marketing data to the FDA that contained evidence of serious health concerns with IV abuse of the reformulated product, such as thrombotic thrombocytopenic purpura and an outbreak of HIV infections in Indiana
 - High molecular weight of the polyethylene oxide (PEO) coating that became lodged in the arterioles of the kidneys of IV abusers

2017 (July)

- FDA recommended Endo remove Opana ER from market, and Endo did so



<https://www.fda.gov/oc/2017/03/20170320-opana-er-reformulation>

25

FDA Opioid Timeline

Reformulation of Opana ER (2006)
2011

1. All ER/LA Opioids REMS: Prescriber Voluntary CE
2. Opana ER reformulated to avoid IN Abuse (IV Spiked)

- 2010
1. Reformulation of OxyContin (OP)
 2. Propoxyphene Voluntary Withdrawal Recommended

- 2013
1. FDA ADF Opioid Extra ADF Studies "Category 3"
 2. Original Opana ER Allowed to Stay on Market
 3. Recommended HCP be CII



<https://www.fda.gov/oc/2017/03/20170320-opana-er-reformulation>

26

FDA Opioid Timeline

Evzio
Embeda (ADF)
Hysingia (ADF)
2014

2016
Xtampza ER
Probuphine (Bup Implant)

1. Loperamide Blister/Single-Dose Packs
 2. Evaluated Hydexor (Hydrocodone/APAP/Pro methazine)
 3. Targeted Online Opioids
 4. Apazac
- 2018

2015
Zohydro ER
OxyContin >11yo Opioid Tolerant
Morphine ER
Narcain Nasal Spray

- 2017
1. Arymo ER
 2. RoxyBond IR
 3. Sublocade (Bup QM)
 4. Reformulated Opana ER Removed from Market (FDA Recommended, Endo Volunteered)
 5. FDA ADF Studies Guidance PO, IV, IN, Sublimation (Smoking)

2019
Dsuvia (sufentanil)
Support Act (Disposal Bags)
OTC Naloxone Discussions



<https://www.fda.gov/oc/2017/03/20170320-opana-er-reformulation>

27

Benz-hydrocodone/APAP

- Prodrug of hydrocodone (+APAP) covalently bonded with benzoic acid
 - Benzoic acid: typical food preservative
 - Ligand-Activated Technology (LAT[®]): GI tract activation
 - Also being studied with a methylphenidate prodrug

Clinical Pharmacology Online Database: 2018
Apaxor Package Insert: 2018

28

Benz-hydrocodone/APAP

- Controlled Substance Class 2 (just as hydrocodone/apap)
- Indicated for the short-term (*no more than 14 days*) management of *acute* pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
 - NOT FDA approved as an abuse-deterrent formulation (ADF) opioid
 - Benzhydrocodone/APAP 6.12/325mg = hydrocodone/APAP 7.5/325mg

Clinical Pharmacology Online Database: 2018
Apaxor Package Insert: 2018

29

FDA ADF Studies

Category 1

In Vitro
Manipulation &
Extraction

Category 2

Pharmacokinetic
(In Vivo)

Category 3

Clinical Abuse Potential
(In Vivo)
Drug Liking & Take Again

Category 4

Post-Marketing

https://www.fda.gov/oc/2018/08/2018-08-01-02-03-04-05-06-07-08-09-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34-35-36-37-38-39-40-41-42-43-44-45-46-47-48-49-50-51-52-53-54-55-56-57-58-59-60-61-62-63-64-65-66-67-68-69-70-71-72-73-74-75-76-77-78-79-80-81-82-83-84-85-86-87-88-89-90-91-92-93-94-95-96-97-98-99-100-101-102-103-104-105-106-107-108-109-110-111-112-113-114-115-116-117-118-119-120-121-122-123-124-125-126-127-128-129-130-131-132-133-134-135-136-137-138-139-140-141-142-143-144-145-146-147-148-149-150-151-152-153-154-155-156-157-158-159-160-161-162-163-164-165-166-167-168-169-170-171-172-173-174-175-176-177-178-179-180-181-182-183-184-185-186-187-188-189-190-191-192-193-194-195-196-197-198-199-200-201-202-203-204-205-206-207-208-209-210-211-212-213-214-215-216-217-218-219-220-221-222-223-224-225-226-227-228-229-230-231-232-233-234-235-236-237-238-239-240-241-242-243-244-245-246-247-248-249-250-251-252-253-254-255-256-257-258-259-260-261-262-263-264-265-266-267-268-269-270-271-272-273-274-275-276-277-278-279-280-281-282-283-284-285-286-287-288-289-290-291-292-293-294-295-296-297-298-299-300-301-302-303-304-305-306-307-308-309-310-311-312-313-314-315-316-317-318-319-320-321-322-323-324-325-326-327-328-329-330-331-332-333-334-335-336-337-338-339-340-341-342-343-344-345-346-347-348-349-350-351-352-353-354-355-356-357-358-359-360-361-362-363-364-365-366-367-368-369-370-371-372-373-374-375-376-377-378-379-380-381-382-383-384-385-386-387-388-389-390-391-392-393-394-395-396-397-398-399-400-401-402-403-404-405-406-407-408-409-410-411-412-413-414-415-416-417-418-419-420-421-422-423-424-425-426-427-428-429-430-431-432-433-434-435-436-437-438-439-440-441-442-443-444-445-446-447-448-449-450-451-452-453-454-455-456-457-458-459-460-461-462-463-464-465-466-467-468-469-470-471-472-473-474-475-476-477-478-479-480-481-482-483-484-485-486-487-488-489-490-491-492-493-494-495-496-497-498-499-500-501-502-503-504-505-506-507-508-509-510-511-512-513-514-515-516-517-518-519-520-521-522-523-524-525-526-527-528-529-530-531-532-533-534-535-536-537-538-539-540-541-542-543-544-545-546-547-548-549-550-551-552-553-554-555-556-557-558-559-560-561-562-563-564-565-566-567-568-569-570-571-572-573-574-575-576-577-578-579-580-581-582-583-584-585-586-587-588-589-590-591-592-593-594-595-596-597-598-599-600-601-602-603-604-605-606-607-608-609-610-611-612-613-614-615-616-617-618-619-620-621-622-623-624-625-626-627-628-629-630-631-632-633-634-635-636-637-638-639-640-641-642-643-644-645-646-647-648-649-650-651-652-653-654-655-656-657-658-659-660-661-662-663-664-665-666-667-668-669-670-671-672-673-674-675-676-677-678-679-680-681-682-683-684-685-686-687-688-689-690-691-692-693-694-695-696-697-698-699-700-701-702-703-704-705-706-707-708-709-710-711-712-713-714-715-716-717-718-719-720-721-722-723-724-725-726-727-728-729-730-731-732-733-734-735-736-737-738-739-740-741-742-743-744-745-746-747-748-749-750-751-752-753-754-755-756-757-758-759-760-761-762-763-764-765-766-767-768-769-770-771-772-773-774-775-776-777-778-779-780-781-782-783-784-785-786-787-788-789-790-791-792-793-794-795-796-797-798-799-800-801-802-803-804-805-806-807-808-809-810-811-812-813-814-815-816-817-818-819-820-821-822-823-824-825-826-827-828-829-830-831-832-833-834-835-836-837-838-839-840-841-842-843-844-845-846-847-848-849-850-851-852-853-854-855-856-857-858-859-860-861-862-863-864-865-866-867-868-869-870-871-872-873-874-875-876-877-878-879-880-881-882-883-884-885-886-887-888-889-890-891-892-893-894-895-896-897-898-899-900-901-902-903-904-905-906-907-908-909-910-911-912-913-914-915-916-917-918-919-920-921-922-923-924-925-926-927-928-929-930-931-932-933-934-935-936-937-938-939-940-941-942-943-944-945-946-947-948-949-950-951-952-953-954-955-956-957-958-959-960-961-962-963-964-965-966-967-968-969-970-971-972-973-974-975-976-977-978-979-980-981-982-983-984-985-986-987-988-989-990-991-992-993-994-995-996-997-998-999-1000

30

Category 3: Abuse Potential Studies

Physically manipulated products compared to regular product

- Cutting
- Grafting
- Milling
- Chewing
- +/- Heat

Routes of Administration

- Ingestion (Oral Route)
 - Oral bioavailability
- Injection (Parenteral Route)
 - Extractability and syringeability
- Insufflation (Nasal Route)
 - Nasal bioavailability & PD effects
- Smoking (Inhalation Route)
 - Ability to sublimate



<https://www.fda.gov/oc/ohrt/04-08-17.pdf>

31

Category 3: Abuse Potential Studies

In Vitro Studies	In Vivo Studies
Extractability Studies	Nasal & Oral PK
Performed at Both Room Temp & Elevated Temp	Multiple Strengths Tested
Solvents • Level 1: Deionized water • Level 2: vinegar, 0.2% baking soda solution, 40% ethanol, & carbonated drink • Level 3: 100% ethanol, 100% isopropyl alcohol, acetone, 0.1 N HCl, & 0.1 N NaOH	Agonist/antagonist levels



<https://www.fda.gov/oc/ohrt/04-08-17.pdf>

32


So who made the cut...pun intended



33

Xtampza ER®

- DETERx Technology
 - Waxy microspheres solidify in a needle
- FDA ADF Approved
 - IN, IV, & PO
- Take with food
 - GI activated, not pH
- Can be opened and sprinkled into a G-Tube or on food



PainWeek

37

Xtampza ER (oxycodone) Dosage	Equivalent to	Extended-release Oxycodone HCl Dosage
9 mg		10 mg
13.5 mg		15 mg
18 mg		20 mg
27 mg		30 mg
36 mg		40 mg
<hr/>		
27 mg + 27 mg		60 mg
36 mg + 36 mg		80 mg

PainWeek

38

OxyContin®

- Original formulation (1996-2009): "OC" Imprint
- Newer formulation (2010-present): "OP" Imprint


Strength	10 mg	15 mg	20 mg	30 mg	40 mg	80 mg
Comparison of original (first) versus reformulated OxyContin® tablets (second).						

PainWeek

39

OxyContin®

- RESISTEC technology
 - Forms a viscous gel with water
- ADF Category 3 study (IN/IV)
 - 57% reduction in drug liking
 - 43% no reduction in drug liking
- Phase 4
 - ~50% decrease in doctor chopping, overdoses, & poison center calls (heroin replaced?)
- Q12h dosing ???



Original OxyContin®

New abuse-deterrent OxyContin®



40



Homophone

the same sound

right ✓	see 👁️	hair 👱
write ✍️	sea 🌊	hare 🐰



41

Oxy-Crisping

Tools of the Trade

- Grater (PediEgg)
- Ceramic/glass plate
- Paper towel
- Microwave
- Fridge/freezer





42

Oxy-Crisping



Tools of the Trade

- Grater  (lemon zester)
- Ceramic/glass plate
- Paper towel
- Microwave
- Fridge/freezer



PainWeek

www.hs.nyu.edu

43

FDA Approved ADF Opioids on US Market

(July 2020)

Medicine	Product	FDA ADF Approval			Formulation
oxycodone	Xtampza ER®	IN	IV	PO Chew	ER Capsule
	OxyContin®	IN	IV		ER Tablet
hydrocodone	Hysingla®	IN	IV	PO Chew	ER Tablet
morphine	Embeda®	IN		PO Crush	ER Tablet
	Arymo®		IV		
	MorphaBond®	IN	IV		


PainWeek

44

Hysingla®

- RESISTEC Technology (*Same as OxyContin)
 - Forms a viscous gel around water
- ADF Category 3 studies (IN, IV, & PO): ~80% reduction in drug liking

HYdrocodone
SINGle dose
Long Acting



PainWeek

45

Hysingla®

Hydrocodone/paral 10mg/325mg
1 T q 4 to 6 h
???

Painweek

46

FDA Approved ADF Opioids on US Market (July 2020)

Medicine	Product	FDA ADF Approval			Formulation
oxycodone	Xtampza ER®	IN	IV	PO Chew	ER Capsule
	OxyContin®	IN	IV		ER Tablet
hydrocodone	Hysingla®	IN	IV	PO Chew	ER Tablet
morphine	Embeda®	IN		PO Crush	ER Tablet
	Arymo®		IV		
	MorphaBond®	IN	IV		

Painweek

47

Arymo®


- Guardian technology (polymer matrix)
 - Physical & chemical barrier
- FDA ADF approved for IV
- Oxycodone product in pipeline

Painweek

48

MorphaBond®

- Sentry Bond Technology
- Dose every 8 to 12 hours
- Can be taken +/- food
- FDA ADF approved for IV & IN



15 mg


30 mg

60 mg

100 mg

PainWeek

49



50

Embeda®

- Sequestered naltrexone induces withdrawal if abused and ingested
- FDA ADF approved IN & PO
—Only FDA ADF opioid originally w/o IV
- Morphine:naltrexone ratio 100:4

EMBEDA vs IR MORPHINE Oral IR (Study 1)^{1,2}


EMBEDA intact vs EMBEDA crushed in solution vs IR morphine in solution vs placebo

EMBEDA vs ER MORPHINE Oral ER (Study 2)^{1,2}

EMBEDA crushed in solution vs ER morphine crushed in solution vs placebo

EMBEDA vs ER MORPHINE Intranasal (Study 3)^{1,2}

Crushed EMBEDA vs crushed ER morphine vs placebo



Actual pellets are between 1.0 mm and 1.7 mm in diameter

PainWeek

51

Embeda®

EMBEDA is available in 6 dosage strengths¹



PainWeek

52

MAT Buprenorphine Products with Naloxone...

FORMULATION	STRENGTH			
Sublingual Tablet	2mg BUP 0.5mg NX	-	8mg BUP 2mg NX	-
Sublingual Film	2mg BUP 0.5mg NX	4mg BUP 1mg NX	8mg BUP 2mg NX	12mg BUP 3mg NX

PainWeek

53

Buprenorphine vs Naloxone

Bluelight

Lazylazzyoe (9/1/2010, 5:57am)

As someone who regularly injects Suboxone, I prefer injecting Suboxone instead of using sublingual mainly because of the efficacy. I can inject 1 to 2mg and be good for an entire day, compared to 4mg sublingual. It also takes affect in 15 minutes instead of 90 minutes.

You do have to be careful though, it is much easier to precipitate withdrawal this way. Wait a little longer for your induction, even longer if coming down off methadone.

The other thing that gets me is that I buy my Suboxone on the street, because between the doc and the pharmacy I'd be paying \$150/month & \$7.50/pill. If the doc would just prescribe Subtex, I could get it generic and do it legit for about the same cost. It drives me nuts as Suboxone is just as easy to abuse as the Subutex. Not to mention the whole pain management specialist thing is a big scam. There's no reason why a regular doc can't prescribe this schedule 3 drug.

Dread (10/1/2010, 2:08am)

Naloxone was put in there to trick the FDA, and it worked! It was put in to extend the patent, they had to come up with a "new" product to keep the big bucks coming in.

PainWeek

www.bluelight.org

54

Buprenorphine vs Naloxone

Package Insert

5.2 Risk of Respiratory and Central Nervous System (CNS) Depression

Buprenorphine has been associated with life-threatening respiratory depression and death. Many, but not all, post-marketing reports regarding coma and death involved misuse by self-injection or were associated with the concomitant use of buprenorphine and benzodiazepines or other CNS depressants, including alcohol. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBOXONE sublingual film [see Warnings and Precautions (5.3), Drug Interactions (7)].

... active substantial heroin or other full mu-opioid dependence. However, clinicians should be aware that some opioid-dependent persons, particularly those with a low level of full mu-opioid physical dependence or those whose opioid physical dependence is predominantly to buprenorphine, abuse buprenorphine/naloxone combinations by the intravenous or intranasal route. In methadone-maintained patients and heroin-



Suboxone Full Prescribing Information, February 27, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022144b02b1.pdf

55

Buprenorphine Battles...



THE UNITED STATES DEPARTMENT OF JUSTICE

FOR IMMEDIATE RELEASE Tuesday, April 9, 2019
Indivior Inc. Indicted for Fraudulently Marketing Prescription Opioid
Company Allegedly Lied to Doctors and Public Health Care Benefit Programs About the Safety and Diversion Risks of Suboxone Film

CLERK'S OFFICE U.S. DISTRICT COURT
AT ABRINGDON, VA
FILED
APR 09 2019
JULIA C. DUGLEY, CLERK
BY: *[Signature]*
DEPUTY CLERK
Case No. 1:19-cr-0016
UNITED STATES OF AMERICA)
v.)
INDIVIOR INC. (a/k/a Reckitt Benckiser)
Pharmaceuticals Inc.) and)
INDIVIOR PLC)
Violations:)
18 U.S.C. §§ 2, 1341, 1343, 1347, 1349



<https://www.justice.gov/opa/pr/2019/04/19-cv-0016-indivior-inc-indicted-fraudulently-marketing-prescription-opioid>
<https://www.justice.gov/opa/pr/2019/04/19-cv-0016-indivior-inc-indicted-fraudulently-marketing-prescription-opioid>

56

Buprenorphine Battles...but the War???

BUSINESS NEWS | JULY 10, 2019 2:10 PM | UPDATED 2:10 PM EDT

Reckitt to pay \$1.4 billion to end opioid addiction treatment probes

Steve Zlotnik, Reuters, Pittsburgh, Pa.

4 MIN READ

(Reuters) - Reckitt Benckiser (RBL) has agreed to pay up to \$1.4 billion (\$1.1 billion) to end U.S. federal investigations into the marketing of an opioid addiction treatment by its former business Indivior, lifting a cloud that has been hanging over the British company for years.

Separately on Thursday, Indivior raised its full-year profit and revenue guidance after Suboxone lost market share at a slower pace than expected, sending its shares 35% higher.



<https://www.reuters.com/article/indivior-reckitt-receives-14-billion-to-end-opioid-addiction-treatment-probes/indivior-reckitt-receives-14-billion-to-end-opioid-addiction-treatment-probes-idUSKCN190001907001>

57

Buprenorphine Improves & Saves Lives

When Utilized as Approved by the FDA

PainWeek

58

FDA Approved ADF Opioids on US Market

(July 2020)

Medicine	Product	FDA ADF Approval			Formulation
oxycodone	Xtampza ER®	IN	IV	PO Chew	ER Capsule
	OxyContin®	IN	IV		ER Tablet
hydrocodone	Hysingla®	IN	IV	PO Chew	ER Tablet
morphine	Embeda®	IN		PO Crush	ER Tablet
	Arymo®		IV		
	MorphaBond®	IN	IV		

PainWeek

59

ADFs, At What Cost?

Chemical Barrier

Physical Barrier

Aversion

Combination of Any

Non-ADF Opioids	ADF Opioids
\$5.82 Average Cost	\$11.60 Average Cost \$6.86 Break-Even Cost

Agonist/antagonist opioid combinations

Delivery System

Prodrug

Conflicts of Interest


Aetna
Anthem
Blue Cross Blue Shield of Massachusetts
Blue Shield of California
Harvard Pilgrim Health Care
Kaiser Permanente
Partners Healthcare
Premier Blue Cross
United HealthCare
Washington State Health Care Authority

PainWeek

60

States Mandating (By Law) ADF Opioid Coverage

- Massachusetts (2014)
- Maine (2015)
- Maryland (2015)
- Florida (2016)
- West Virginia (2016)



Painweek

Source: Multistate Issue Management Service. View as of April 15, 2017.

MULTISTATE

61



Painweek

62

ADF Opioid Pipeline TAAP


- TAAP (Trypsin Activated Abuse Protection)
 - Trypsin is found only in the small intestine
- MPAR (Multi-Pill Abuse Resistance)
 - A small amount of trypsin inhibitor (soybeans & egg whites) added to each pill not affecting opioid release
 - If multiple pills are ingested (on purpose or accidentally) the trypsin inhibitor blocks the activation of the opioid prodrug

Painweek

<http://www.american.com/story/multi-act>

63

Trypsin → Protein Breakdown



Painweek


<http://www.physiologymodels.info/digestion/proteins.htm>

64

ADF Opioid Pipeline TAAP & MPAR

- Oxycodone (PF614)
 - 12-hour $t_{1/2}$ (true BID dosing)
- Hydromorphone ER (PF329)
- Amphetamine (PF8001/8026)
 - ADHD
- R-Methadone (PF26810)
 - Medication assisted treatment

PF614 PROVEN TO BE TAMPER-PROOF



TAAP™: PHASE I CLINICAL DATA

Painweek

tamper-resistant technology

www.painweek.com/oxycodone

65



Painweek

66

Audience Question #1

A 45yo female patient with chronic lower back pain and hypertension presents to your practice as a new patient already having utilized hydrocodone, for many years. While performing an opioid risk assessment, you find out that she is living in a house with a spouse who has a substance-use disorder. You would like to convert the patient's current non-abuse-deterrent formulation (ADF) ER opioid to an FDA approved ADF ER opioid formulation that is readily available on the US market. Which of the following is the most appropriate selection based on this intention?

- a) Zohydro ER
- b) Hysingla
- c) Vantrela
- d) Xtampza ER



67

Audience Question #1

A 45yo female patient with chronic lower back pain and hypertension presents to your practice as a new patient already having utilized hydrocodone, for many years. While performing an opioid risk assessment, you find out that she is living in a house with a spouse who has a substance-use disorder. You would like to convert the patient's current non-abuse-deterrent formulation (ADF) ER opioid to an FDA approved ADF ER opioid formulation that is readily available on the US market. Which of the following is the most appropriate selection based on this intention?

- a) Zohydro ER
- b) **HYSINGLA [CORRECT ANSWER]**
- c) Vantrela
- d) Xtampza ER

Medicine	Product
oxycodone	Xtampza ER®
	OxyContin®
hydrocodone	Hysingla®
	Embeda®
morphine	Arymo®
	MorphaBond®



68

Audience Question #2

A 55yo male patient with chronic lower back pain and DM2 presents to your practice as a new patient already having utilized oxycodone for many years. Upon performing an opioid risk assessment, you find that he is of high risk for opioid abuse. He also states that he would prefer an opioid medication that can be sprinkled on his food instead of swallowing the pill whole. You would like to convert the patient's current non-abuse-deterrent formulation (ADF) ER opioid to an FDA approved ADF ER opioid formulation that is readily available on the US market. Which of the following is the most appropriate selection based on this intention?

- a) Embeda
- b) Zohydro ER
- c) OxyContin
- d) Xtampza ER



69

Audience Question #2

A 55yo male patient with chronic lower back pain and DM2 presents to your practice as a new patient already having utilized oxycodone for many years. Upon performing an opioid risk assessment, you find that he is of high risk for opioid abuse. He also states that he would prefer an opioid medication that can be sprinkled on his food instead of swallowing the pill whole. You would like to convert the patient's current non-abuse-deterrent formulation (ADF) ER opioid to an FDA approved ADF ER opioid formulation that is readily available on the US market. Which of the following is the most appropriate selection based on this intention?

- a) Embeda
- b) Zohydro ER
- c) OxyContin
- d) XTAMPZA ER [CORRECT ANSWER]

Medicine	Product
oxycodone	Xtampza ER®
	OxyContin®
hydrocodone	Hysingla®
morphine	Embeda®
	Arymo®
	MorphoBond®



70

Audience Question #3

Which of the following states have legislation mandating the prescription insurance benefit coverage of abuse-deterrent formulation (ADF) opioid medications in at least some manner?

- a) Massachusetts
- b) Maryland
- c) Florida
- d) All of the above



71


Audience Question #3

Which of the following states have legislation mandating the prescription insurance benefit coverage of abuse-deterrent formulation (ADF) opioid medications in at least some manner?


- a) Massachusetts
 - b) Maryland
 - c) Florida
 - d) ALL OF THE ABOVE [CORRECT ANSWER]
- | |
|------------------------|
| ▪ Massachusetts (2014) |
| ▪ Maine (2015) |
| ▪ Maryland (2015) |
| ▪ Florida (2016) |
| ▪ West Virginia (2016) |



72




73



74

Discussion

Mark Garofoli, PharmD, MBA, BCGP, CPE
LinkedIn: Mark Garofoli



DIAMORPHINE HYDROCHLORIDE
5 mg, 10 mg, 30 mg, 100 mg or 500 mg FOR INJECTION

PACKAGE LEAFLET'S INFORMATION FOR THE USER

Read all of this leaflet carefully before you start using this medicine.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or nurse.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed on this leaflet. See section 4.

HOW TO USE IT

1. What Diamorphine is and what it is used for
2. Before you receive Diamorphine
3. How to receive Diamorphine
4. Possible side effects
5. How to store Diamorphine
6. Further information

WHAT DIAMORPHINE IS AND WHAT IT IS USED FOR

Diamorphine is a narcotic analgesic.

Diamorphine is used to treat severe pain associated with:

- terminal illness
- heart attack
- fluid on the lungs.

75